Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06319872 · ClinicalTrials.gov registry record · Phase 1
The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration
A Phase 1 study of Alcohol Use Disorder and Age-related Macular Degeneration, sponsored by University of Rochester.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT06319872 is a Phase 1 study of Alcohol Use Disorder and Age-related Macular Degeneration that is actively recruiting participants, run by University of Rochester. The registered enrollment target is 15 participants, below the 328-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06319872, a Phase 1 study of Alcohol Use Disorder and Age-related Macular Degeneration, is actively recruiting participants, sponsored by University of Rochester.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
Oral disulfiram (Antabuse®) has been shown to improve image-forming vision in animal models with retinal degeneration due to its ability to decrease Retinoic Acid synthesis and consequently reduce hyperactivity in the inner retina. The investigator will aim to evaluate the impact of oral disulfiram on the vision of patients with retinal degeneration who are being treated with the drug in the management of their concurrent alcohol use disorder.
Conditions Studied
Interventions
- DRUG Oral disulfiram
Study Locations (1)
New York
- Flaum Eye Institute, University of Rochester Medical Center - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2025-05-19 |
| Est. Completion | 2029-05-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06319872
The ClinicalTrials.gov registry entry for NCT06319872 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 328-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (95% lower). The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Alcohol Use Disorder appearing as the primary indexed condition, and to 1 intervention - of which Oral disulfiram is the first listed.
NCT06319872 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT06319872 about?
NCT06319872 is a clinical study titled "The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration". Oral disulfiram (Antabuse®) has been shown to improve image-forming vision in animal models with retinal degeneration due to its ability to decrease Retinoic Acid synthesis and consequently reduce hyperactivity in the inner retina. The investigator will aim to evaluate the impact of oral disulfiram ...
What is the current status of trial NCT06319872?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2025-05-19. Estimated completion is 2029-05-19.
What conditions does trial NCT06319872 study?
This clinical trial studies the following conditions: Alcohol Use Disorder, Age-related Macular Degeneration, Retinitis Pigmentosa, Stargardt Disease, Retinal Dystrophies.
What interventions are being tested in trial NCT06319872?
The interventions under investigation include: Oral disulfiram (DRUG).
Who is sponsoring clinical trial NCT06319872?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06319872 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alcohol Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Intranasal Insulin for Treatment of Alcohol Use Disorder
RECRUITING · Phase 1
-
Acute Effects of Alcohol on PET Imaging of Phosphodiesterase-4B (PDE4B)
RECRUITING · Phase 1
-
Environment and Alcohol: A Pilot Study
RECRUITING · Phase 1
-
PET Imaging of Phosphodiesterase-4B (PDE4B) in Alcohol Use Disorder
RECRUITING · Phase 1
-
Sex Differences in the Response to Abstinence From Alcohol.
RECRUITING · Phase 1
-
PT150 Drug for Use in Alcohol Use Disorder
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.